Biotechnology News and Research

RSS

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Azaya Therapeutics, Inc. announced today that the Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for its lead product “ATI-1123,” a novel and improved formulation of Taxotere® (docetaxel), a leading chemotherapy drug with worldwide annual sales of over $2.8 billion.

10 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

InNexus Biotechnology, XERIS Pharmaceuticals collaborate in development of novel antibody delivery system

InNexus Biotechnology Inc. and XERIS Pharmaceuticals, Inc. announced today a research collaboration in which the companies will pursue development of a potential subcutaneous delivery of InNexus’ Dynamic Cross Linking (DXL™) antibodies using XERIS’ proprietary formulation-injection technologies.

10 Dec 2009

Vicor's PD2i nonlinear algorithm selected for CRY cardiac screening initiative

David H. Fater, CEO of Vicor Technologies, Inc., today announced that its PD2i® nonlinear algorithm has been selected by Dr. Sanjay Sharma to be used in a month-long cardiac screening initiative to be held in South East London in April 2010.

10 Dec 2009

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

Oncothyreon Inc. today announced that Merck KGaA of Darmstadt, Germany, has initiated a Phase 3 trial of Stimuvax(R) (BLP25 liposome vaccine) in Asian patients with advanced non-small cell lung cancer (NSCLC). The trial, named INSPIRE (Stimuvax trial In Asian NSCLC Patients: Stimulating Immune Response), is anticipated to enroll approximately 420 patients in China, Hong Kong, South Korea, Singapore and Taiwan.

10 Dec 2009

YM BioSciences announces results of collaborative antibody development program

YM BioSciences Inc., today announced the first results of a collaborative program between YM and the National Research Council of Canada's Biotechnology Research Institute (NRC-BRI). Utilizing YM's IntelliMab(TM) technology, the program is designed to generate novel antibodies that target cell surface receptors associated with cancer, uniquely optimized to produce efficacy with reduced toxicities.

10 Dec 2009

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010.

10 Dec 2009

Convergence between EDC and RTSM solutions simplifies workflow management

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (Nasdaq: PRXL), today introduced unique product convergence between its DataLabs® EDC solution and ClinPhone® Randomization and Trial Supply Management (RTSM) technologies.

From Parexel 10 Dec 2009

Public health information website to provide information about advanced disinfectants launched

TouchSurfaces.Org launches a public health information website alerting visitors on how the hard surfaces in the home, the work place, and in public venues can act as host to a multitude of infectious viruses and bacteria including H1N1, MRSA, HIV, and others.

10 Dec 2009

Vivakor announces acquisition strategy for the next 12 months

Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced its acquisition strategy for the next 12 months. Executive Chairman, Matt Nicosia detailed the key points of the strategy:

10 Dec 2009

Cubist Pharmaceuticals integrates Reprints Desk's document delivery service and QUOSA's Virtual Library

Reprints Desk, Inc., and QUOSA, Inc., today announced that Cubist Pharmaceuticals has become the first shared customer to activate integration between Reprints Desk's STM Document Delivery service with QUOSA's Virtual Library, which facilitates copyright-compliant article archiving and scientific literature re-use.

10 Dec 2009

Cell transplants may yield new therapies for dementia patients

Nerve cells transplanted into brain-damaged rats helped them to fully recover their ability to learn and remember, probably by promoting nurturing, protective growth factors, according to a new study.

10 Dec 2009

ACR Image Metrix presents computerized system validation for imaging clinical trials at the DIA forum

Brenda K. Young, BA, CCRA, senior director of clinical operations at ACR Image Metrix™, an imaging contract research organization (CRO) located in Philadelphia, Pennsylvania, has presented her experience in computerized system validation to the Drug Information Association (DIA) 3rd Annual Clinical Forum held in Nice, France, on October 19, 2009.

10 Dec 2009

Medifocus begins common stock trading on OTC Pink Sheets market

Medifocus, Inc., a biotechnology company focused on the commercialization of a proprietary and patented microwave focused heat system for the treatment of breast cancer is pleased to announce that the Company had begun trading its common stock on the OTC Pink Sheets market on Dec. 7, 2009.

10 Dec 2009

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today announced that it has signed an exclusive License Agreement with Wayne State University to key intellectual property covering discoveries of biomarkers of ovarian cancer.

10 Dec 2009

FDA launches workshop to simplify orphan drug development

The U.S. Food and Drug Administration (FDA) has announced the launch of an orphan drug workshop series--an opportunity for biotechnology companies, pharmaceutical firms, academics and other interested parties to spend two days creating applications for orphan status designation, under the guidance of staff from FDA's Office of Orphan Products Development (OOPD).

9 Dec 2009

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Lentigen Corporation, a biotechnology company specializing in the development and manufacture of lentiviral gene delivery technologies, announced today that it has received a National Institutes of Health (NIH) small business innovation research (SBIR) grant for a program on "A Novel Method of Generating Hepatitis C Virus-Like Particles using Lentivirus". In this program, Lentigen will collaborate with Epixis SA (Paris, France).

9 Dec 2009

Newly created line of skin care products based on ISCO’s proprietary Parthenogenic Stem Cells

Lifeline Skin Care, Inc, a wholly owned subsidiary of International Stem Cell Corporation, announced today that it has retained the services of a highly experienced expert in the skin care industry, Raulee Marcus, to help design a marketing program for its newly created line of skin care products based on ISCO’s proprietary Parthenogenic Stem Cells.

9 Dec 2009

Protalix Biotherapeutics completes NDA submission for taliglucerase alfa

Protalix Biotherapeutics, Inc. today announced the completion of its New Drug Application (NDA) submission with the U.S. Food and Drug Administration (FDA) for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) for the potential treatment of Gaucher’s disease.

9 Dec 2009

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial stage biotechnology company with a primary focus in oncology, today announced that it has been ranked by the Orange County Register as one of Orange County’s Top Work Places for 2009.

9 Dec 2009

Biotechnology News and Research

FDA approves Azaya Therapeutics' Taxotere for Phase I clinical study

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

InNexus Biotechnology, XERIS Pharmaceuticals collaborate in development of novel antibody delivery system

Vicor's PD2i nonlinear algorithm selected for CRY cardiac screening initiative

Merck commences Stimuvax Phase 3 trial in Asian patients with NSCLC

YM BioSciences announces results of collaborative antibody development program

Eli Lilly provides financial guidance for 2010

Convergence between EDC and RTSM solutions simplifies workflow management

Public health information website to provide information about advanced disinfectants launched

Vivakor announces acquisition strategy for the next 12 months

Cubist Pharmaceuticals integrates Reprints Desk's document delivery service and QUOSA's Virtual Library

Cell transplants may yield new therapies for dementia patients

ACR Image Metrix presents computerized system validation for imaging clinical trials at the DIA forum

Medifocus begins common stock trading on OTC Pink Sheets market

Arrayit Diagnostics signs exclusive License Agreement with Wayne State University

FDA launches workshop to simplify orphan drug development

NIH awards Lentigen a SBIR grant for program to generate Hepatitis C Virus-Like Particles

Newly created line of skin care products based on ISCO’s proprietary Parthenogenic Stem Cells

Protalix Biotherapeutics completes NDA submission for taliglucerase alfa

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News